{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
belzutifan
to a specific field?
There is one exact (name or code) match for belzutifan
Status:
US Approved Rx
(2021)
Source:
NDA215383
(2021)
Source URL:
First approved in 2021
Source:
NDA215383
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Belzutifan (PT2977) is an orally active, small molecule inhibitor of hypoxia-inducible factor (HIF)-2alpha (HIF-2a). Upon oral administration, HIF-2alpha inhibitor PT2977 binds to and blocks the function of HIF-2alpha, thereby preventing HIF-2alpha heterodimerization and its subsequent binding to DNA. This results in decreased transcription and expression of HIF-2alpha downstream target genes, many of which regulate hypoxic signaling. This inhibits cell growth and survival of HIF-2alpha-expressing tumor cells. HIF-2alpha, the alpha subunit for the heterodimeric transcription factor HIF-2, is overexpressed in many cancers and promotes tumorigenesis.
Showing 1 - 6 of 6 results
Status:
US Approved Rx
(2021)
Source:
NDA215383
(2021)
Source URL:
First approved in 2021
Source:
NDA215383
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Belzutifan (PT2977) is an orally active, small molecule inhibitor of hypoxia-inducible factor (HIF)-2alpha (HIF-2a). Upon oral administration, HIF-2alpha inhibitor PT2977 binds to and blocks the function of HIF-2alpha, thereby preventing HIF-2alpha heterodimerization and its subsequent binding to DNA. This results in decreased transcription and expression of HIF-2alpha downstream target genes, many of which regulate hypoxic signaling. This inhibits cell growth and survival of HIF-2alpha-expressing tumor cells. HIF-2alpha, the alpha subunit for the heterodimeric transcription factor HIF-2, is overexpressed in many cancers and promotes tumorigenesis.
Status:
US Approved Rx
(2013)
First approved in 1958
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
NCT00915733: Phase 4 Interventional Completed Myocardial Infarction
(2009)
Source URL:
Class:
PROTEIN
